Free tool
FAERS Monitor: Peridex
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 019028 or its brand name (Peridex, Chlorhexidine Gluconate). Reports on generic versions are filed under their own applications.
Reports
8,740
Serious
7,269
83% of reports
Hospitalization
4,221
Death reported
2,883
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- fatigue2,010
- joint swelling1,745
- rash1,726
- pain1,715
- hypersensitivity1,672
- impaired healing1,668
- arthralgia1,624
- weight increased1,624
- folliculitis1,623
- dyspnoea1,605
- stomatitis1,602
- glossodynia1,545
- lower respiratory tract infection1,543
- off label use1,542
- blister1,529
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 41 |
| 2005 | 34 |
| 2006 | 38 |
| 2007 | 63 |
| 2008 | 119 |
| 2009 | 128 |
| 2010 | 187 |
| 2011 | 207 |
| 2012 | 203 |
| 2013 | 95 |
| 2014 | 110 |
| 2015 | 193 |
| 2016 | 314 |
| 2017 | 330 |
| 2018 | 375 |
| 2019 | 366 |
| 2020 | 486 |
| 2021 | 757 |
| 2022 | 666 |
| 2023 | 547 |
| 2024 | 1,349 |
| 2025 | 1,578 |
| 2026 | 553 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,045,419 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| folliculitisSignal | 1,623 | 440.4 | 419.6 | 601,497 |
| glossodyniaSignal | 1,545 | 178.3 | 170.1 | 253,744 |
| impaired healingSignal | 1,668 | 128.8 | 123.1 | 200,897 |
| lower respiratory tract infectionSignal | 1,543 | 84.5 | 80.7 | 123,165 |
| blisterSignal | 1,529 | 67.3 | 64.3 | 97,369 |
| stomatitisSignal | 1,602 | 65.3 | 62.4 | 98,913 |
| joint swellingSignal | 1,745 | 35.3 | 33.8 | 57,587 |
| hypersensitivitySignal | 1,672 | 21.9 | 20.9 | 33,263 |
| weight increasedSignal | 1,624 | 17.6 | 16.8 | 25,452 |
| rashSignal | 1,726 | 9.6 | 9.2 | 13,452 |
| arthralgiaSignal | 1,624 | 9.4 | 9.0 | 12,432 |
| dyspnoeaSignal | 1,605 | 6.8 | 6.5 | 8,194 |
| painSignal | 1,715 | 6.7 | 6.5 | 8,597 |
| fatigueSignal | 2,010 | 6.2 | 6.0 | 9,128 |
| off label useSignal | 1,542 | 4.2 | 4.1 | 3,979 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.